IP Library Granted Patent US 7,462,365
Granted Patent B2
US 7,462,365 · App. 10/688,059 · Granted Dec 9, 2008

Microencapsulation and sustained release of biologically active polypeptides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,462,365
App. No.
10/688,059
Granted
Dec 9, 2008
Kind
B2
Abstract

This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide, a sugar and a salting-out salt.

Claims (18)

1. A composition for the sustained release of a biologically active polypeptide consisting of: a biocompatible polylactide-co-glycolide polymer having dispersed therein a biologically active glucoregulatory polypeptide, a sugar and glycine.

2. The composition of claim 1 , wherein the polypeptide is selected from GLP-1, GLP-2, exendin-3, exendin-4 or a combination thereof.

3. The composition of claim 2 , wherein the polypeptide is present from about 0.01% (w/w) to about 50% (w/w) of the total weight of the composition.

4. The composition of claim 3 , wherein the polypeptide is present in a range from about 0.1% (w/w) to about 30% (w/w) of the total weight of the composition.

5. The composition of claim 4 , wherein the polypeptide is present from about 0.1% (w/w) to about 10% (w/w) of the total weight of the composition.

6. The composition of claim 5 , wherein the polypeptide is present from about 0.5% (w/w) to about 5% (w/w) of the total weight of the composition.

7. The composition of claim 1 , wherein the sugar is present from about 0.01% (w/w) to about 50% w/w of the total weight of the composition.

8. The composition of claim 7 , wherein the sugar is present from about 0.01% (w/w) to about 10% w/w of the total weight of the composition.

9. The composition of claim 8 , wherein the sugar is present from about 0.01% (w/w) to about 5% w/w of the total weight of the composition.

10. The composition of claim 1 , wherein the sugar is selected from a monosaccharide, a disaccharide, a sugar alcohol or a combination thereof.

11. The composition of claim 10 , wherein the sugar is selected from sucrose, trehalose, mannitol and combinations thereof.

12. The composition of claim 10 , wherein the sugar is a disaccharide.

13. The composition of claim 12 , wherein the disaccharide is sucrose, trehalose or a combination thereof.

14. A method of treating a patient suffering from Type 2 diabetes comprising administering a therapeutically effective amount of a sustained release composition according to claim 1 .

15. The composition of claim 1 , wherein the polypeptide is exendin-4.

16. The composition of claim 1 , wherein the sugar is sucrose.

17. The composition of claim 1 , wherein the polypeptide is exendin-4 and the sugar is sucrose.

18. A method of treating a patient suffering from Type 2 diabetes comprising administering a therapeutically effective amount of a sustained release composition according to claim 17 .

Assignments (6)
RELEASE OF PATENT SECURITY AGREEMENT (FIRST LIEN) Recorded Dec 24, 2024
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 069771/0548 →
RELEASE BY SECURED PARTY (SECOND LIEN) Recorded Oct 12, 2012
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
Reel/Frame 029116/0379 →
CONFIRMATORY ASSIGNMENT Recorded Dec 12, 2011
From: ALKERMES, INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 027364/0962 →
PATENT SECURITY AGREEMENT (FIRST LIEN) Recorded Sep 29, 2011
From: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 026994/0186 →
PATENT SECURITY AGREEMENT (SECOND LIEN) Recorded Sep 29, 2011
From: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 026994/0245 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 30, 2008
From: COSTANTINO, HENRY R.; HOTZ, JOYCE M.
To: ALKERMES, INC.
Reel/Frame 022034/0933 →